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Au@Fe3O4 Janus particles (JPs) are heteroparticles with discrete domains deﬁned by different materials.
Their tunable composition and morphology confer multimodal and versatile capabilities for use as
contrast agents and drug carriers in future medicine. Au@Fe3O4 JPs have colloidal properties and surface
characteristics leading to interactions with proteins in biological ﬂuids. The resulting protein adsorption
layer (“protein corona”) critically affects their interaction with living matter. Although Au@Fe3O4 JPs
displayed good biocompatibility in a standardized in vitro situation, an in-depth characterization of the
protein corona is of prime importance to unravel underlying mechanisms affecting their pathophysiology
and biodistribution in vitro and in vivo. Here, we comparatively analyzed the human plasma corona of
Au-thiol@Fe3O4-SiO2-PEG JPs (NH2-functionalized and non-functionalized) and spherical magnetite
(Fe3O4-SiO2-PEG) particles and investigated its effects on colloidal stability, biocompatibility and cellular
uptake. Label-free quantitative proteomic analyses revealed that complex coronas including almost 180
different proteins were formed within only one minute. Remarkably, in contrast to spherical magnetite
particles with surface NH2 groups, the Janus structure prevented aggregation and the adhesion of op-
sonins. This resulted in an enhanced biocompatibility of corona sheathed JPs compared to spherical
magnetite particles and corona-free JPs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bioimaging techniques, including ultrasound, computed X-ray
tomography (CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET), are essential tools not only for scien-
tiﬁc research, but also for clinical diagnostics. The synergistic
combination of multiple comprehensive imaging techniques in
diagnostics enables a faster, more accurate, and physically less
demanding prognosis [1]. These latest developments have
increased scientiﬁc interest and clinical need for multimodal, ingrid.hilger@med.uni-jena.
Ltd. This is an open access article ucontrast agents, which could enhance safety and reduce adverse
effects by limiting the amount and dose of different contrast agents,
improve patient care, and, at the same time, lower costs.
Au nanoparticles display extraordinary optical properties
relying on surface plasmon resonance (SPR), enabling their wide-
spread use and high potential for biomedical applications,
including simultaneous cell-imaging and photothermal therapy
[2e4], multi-photon microscopy [5], and colorimetric sensing of
adsorbed biomolecules [6,7]. Moreover, they are emerging as next
generation contrast agents for computed X-ray tomography (CT)
[8,9]. Similarly, magnetic nanoparticles such as magnetite (Fe3O4)
constitute a class of nanomaterials that has attracted much interest
for biomedical applications [10,11] including therapeutics for hy-
perthermia, drug delivery, and diagnostics [12e14].
Au@Fe3O4 JPs are multifunctional heteroparticles harboring twonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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composition and morphology confer multimodal and versatile ca-
pabilities for use as contrast agents and drug carriers in future
medicine, whose potential applications in different ﬁelds is only
emerging [15e19].
The intrinsic appeal of JPs is their tunable and controllable
asymmetric structure, providing spatially controlled functionalities
down to the nanoscale. Especially biomedical applications proﬁt
from the synergistic potential for multiplexing, multi-level target-
ing, and combination therapies. The availability of two different
surfaces for multiple drug and target loading without steric hin-
drance from other components is of particular importance. In
addition, the two different nanoparticle domains can be used for
different imaging modalities, e.g. gold for X-ray based imaging
[20,21] and magnetite for magnetic resonance imaging (MRI)
[22e24]. The metallic nature of the cores offers versatile combi-
nations of minimal invasive therapy approaches, like photothermal
ablation by exploiting the absorbance of light by the gold and
magnetic hyperthermia by utilizing the superparamagnetic
behavior of iron oxide [12,25e28].
A major downside of most inorganic nanoparticles is their
colloidal instability due to agglomeration based on mutual attrac-
tion by van der Waals forces. As most biomedical applications
require administration of nanoparticles into the body via intrave-
nous injection, an essential prerequisite for the implementation of
bionanotechnological applications is to ensure sufﬁcient colloidal
stability under physiological conditions, i.e. the in vitro and in vivo
biocompatibility is an essential barrier for an application of new
nanomaterials.
After application, the nanoparticles will typically be transported
via the blood system and will react with blood proteins and the
immune system [29e31]. The adhesion of proteins to the nano-
particles in a speciﬁc biological environment determines their fate
in the body. In particular, immune cells can be activated which
provides the clearance of the particles by the mononuclear
phagocyte system [32e34]. Even though nanoparticle protein co-
ronas have been intensively investigated for liposomes or sym-
metric and isotropic polystyrene, magnetite, and silica
nanoparticles [30,35e37], it is yet unclear whether asymmetric and
amphiphilic Au@Fe3O4 nanoparticles exhibit similar features
regarding the formation of a protein corona similar to spherical
nanoparticles [30,38e40]. In view of the widespread biomedical
applications of JPs, they have a similar biodistribution [15] as their
spherical and isotropic component constituent blocks.
Here, we applied a comprehensive experimental approach to
study the formation of a protein corona of Au@Fe3O4 Janus nano-
particles and its effects on the in vitro and in vivo situation. To
unravel the effect of the asymmetric nanoparticle morphology on
the adhesion of plasma proteins, we compared JPs with spherical
Fe3O4 nanoparticles of comparable size and composition. Both
particle types contain a silica shell at the Fe3O4 domain modiﬁed
with a short-chained PEG, while the gold part of the JPs was coated
with thiol groups (Fe3O4-SiO2-PEG vs. Au-thiol@Fe3O4-SiO2-PEG).
Since surface NH2 groups are typically used for further function-
alization of nanoparticles, the magnetite domain of the JPs and the
symmetric Fe3O4 particles were amine functionalized (Fe3O4-SiO2-
PEG-NH2 vs. Au-thiol@Fe3O4-SiO2-PEG-NH2) to gain information
on the impact of surface functionalization and nanoparticle
morphology on the composition of the protein corona. We applied
a well-established quantitative proteomic workﬂow [30,41] for the
detailed characterization of the protein corona. Additionally,
changes in the nanoparticle stability and surface properties were
analyzed by size and zeta potential measurements after incubation
in human plasma. To gain further insight into the pathophysio-
logical effects on cellular metabolism, we compared cellular ATPlevels and intracellular uptake of nanoparticles with a corona and
particles with no corona using human endothelial cells, which
represent the ﬁrst barrier after intravenous (i. v.) injection. Lastly,
the in vivo biodistribution of JPs and their MRI imaging properties
as well as the organ iron content was determined after i.v. appli-
cation, revealing general feasibility of Janus particles as blood pool
contrast agent.
2. Materials and methods
2.1. Synthesis of asymmetric and spherical nanoparticles
The Au@Fe3O4 and spherical Fe3O4 nanoparticles were synthe-
sized as described previously with thiol groups at the gold domain
and a silica-PEG shell at the iron oxide domain (Au-thiol@Fe3O4-
SiO2-PEG and Fe3O4-SiO2-PEG) [15,16]. Gold nanoparticles were
prepared by a modiﬁed procedure [42] followed by the synthesis of
Au@Fe3O4 heteroparticles using a seed-mediated chemical protocol
[43,44]. The heating of 15 mg of Au nanoparticles, 6 mmol (2 mL) of
oleylamine, 6 mmol (2 mL) oleic acid, and 20 mL of 1-octadecene in
an argon atmosphere up to 120 C was followed by the injection of
2 mmol (0.27 mL) of iron pentacarbonyl. Particle collecting was
carried out after cooling down to room temperature by adding
isopropanol (ﬁve times the volume of themixture), a centrifugation
step (9344  g, 10 min) and re-dispersion in hexane. Monodisperse
isotropic iron oxide nanoparticles were synthesized by thermal
decomposition of the iron(III)oleate [45,46] followed by the coating
with a silica-PEG [47]. For comparison of functionalization, NH2-
groups were attached via (3-aminopropyl)-triethoxysilane (APS) to
the iron oxide core.
2.2. Particle characterization
Core sizes, hydrodynamic diameters and charge were deter-
mined by transmission electron microscopy (TEM) (Philips EM 420,
LaB6 cathode, 120 kV acceleration voltage) of 150 individual
nanoparticles, dynamic light scattering (DLS), and zeta potential (z)
measurements (Zeta sizer, Malvern), respectively. For DLS and zeta
potential determinations 50 mg/mL Fe(II)/(III) of nanoparticles were
incubated in water or in human plasma for 1 h at 4 C. All nano-
particle suspensions were centrifuged through a 0.7 M sucrose
cushion at 18.000  g for 25 min to ensure the same conditions
throughout all experiments [30]. The nanoparticle pellets were
suspended in water and transferred into measurement cuvettes
(Malvern). The average hydrodynamic diameter was determined
from 5 measurements. Zeta potential measurements were per-
formed in triplicate, each with 10 runs at 25 C.
2.3. Human blood and plasma preparation
Blood from six different healthy volunteers was transferred to s-
monovettes (citrate coated tubes) (Sarstedt). For plasma prepara-
tion 50 mL blood was collected in a falcon tube (Eppendorf). The
tubes were centrifuged for 12 min at 4000  g to pellet the blood
cells [41]. The plasma supernatant was aliquoted and stored
at80 C. For experiments, plasmawas thawed and centrifuged for
2 min at 12,000  g/4 C to pellet protein precipitates. All experi-
ments were performed according to the requirements of the local
ethics committee.
2.4. Incubation of nanoparticles with human plasma
Nanoparticles (100 mg/mL Fe(II)/(II)) of the different formula-
tions were incubated in 500 mL of plasma for 1 min or 1 h at 4 C. To
pellet the protein-nanoparticle complexes, the nanoparticle plasma
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centrifuged for 25 min at 18,000  g/4 C [30]. The resulting su-
pernatants were used for quantitative protein analysis. The nano-
particle pellets were resuspended in wash buffer (103.5 mM NaCl,
5.3 mM KCl, 5.6 mM Na2HPO4, 1.4 mM KH2PO4, 23.8 mM NaHCO3,
pH 7.4) [41]. Afterward, NP-pellets werewashed with buffer at least
three times by repeated centrifugation; all supernatants were
collected.
To elute the proteins from the nanoparticles for SDS-PAGE, the
pellets were resuspended in SDS-sample buffer (62.5 mM TriseHCl
pH 6.8; 2% w/v SDS, 10% glycerol, 50 mM DTT, 5% 2-
mercaptoethanol, 0.01% w/v bromphenol blue) and boiled for
15 min at 95 C in a water bath.
2.5. Quantitative protein analysis using Bradford
For quantitative analysis of proteins bound to the nanoparticles,
supernatants after nanoparticle centrifugation through the sucrose
cushion were processed for a colorimetric Bradford method [48].
Analysis was performed in triplicate.
2.6. SDS-PAGE
For the SDS-PAGE we used the eluted and boiled protein sam-
ples (see above). A SDS-polyacrylamide gel electrophoresis (PAGE)
(1D) with all samples was carried out using a 12% polyacrylamide
gel [30]. Visualization of the proteins was performed via silver ni-
trate staining as described previously [49].
2.7. Label-free quantitative proteomic analysis of corona
components
After isolation of the nanoparticle protein complexes through
the sucrose cushion and washing the pellets in wash buffer
(103.5 mM NaCl, 5.3 mM KCl, 5.6 mM Na2HPO4, 1.4 mM KH2PO4,
23.8 mM NaHCO3, pH 7.4), they were suspended in 7 M urea, 2 M
thiourea and 2% of CHAPS (all components purchased from Roth).
Eluted corona proteins (20 mg) were subjected to tryptic digestion
using a modiﬁed ﬁlter aided sample preparation protocol as
described in Ref. [50]. Brieﬂy, eluted corona proteins were loaded
on the ﬁlter, and detergents were removed by washing three times
with 8 M urea buffer. The proteins were reduced using DTT, alky-
lated using iodoacetamide, and the excess reagent was quenched
additional DTT and washed through the ﬁlters. Buffer was
exchanged to 50 mM NH4HCO3 and proteins digested overnight by
trypsin (Trypsin Gold, Promega, enzyme to protein ratio of 1:50).
Peptides were recovered after overnight digestion by centrifugation
and two additional washes using 50 mM NH4HCO3. Flow throughs
were combined, lyophilized and redissolved in 20 ml 0.1% formic
acid by soniﬁcation. Tryptic peptide solutions were diluted with
aqueous 0.1% v/v formic acid to a concentration of 200 ng/ml and
spiked with 25 fmol/ul of enolase 1 (Saccharomyces cerevisiae)
tryptic digest standard (Waters Corporation). Nanoscale UPLC
separation of tryptic peptides was performed with a nano Acquity
system (Waters Corporation) equipped with a CSH-C18 1.8 mm,
100 mm  250 mm analytical reversed-phase column (Waters
Corporation) in direct injection mode as described before [50].
300 ng of total protein was injected per technical replicate. Mobile
phase A was water containing 0.1% v/v formic acid, while mobile
phase B was ACN containing 0.1% v/v formic acid. Peptides were
separatedwith a gradient of 5e40%mobile phase B over 34min at a
ﬂow rate of 300 nL/min, followed by a 4-min column rinsewith 90%
of mobile phase B at 500 nl/min. The columns were re-equilibrated
at initial conditions for 6 min. The analytical column temperature
was maintained at 45 C. The lock mass compound, [Glu1]-Fibrinopeptide B (100 fmol/mL), was delivered by the auxiliary
pump of the LC system at 500 nL/min to the reference sprayer of the
NanoLockSpray source of the mass spectrometer.
Mass spectrometric analysis of tryptic peptides was performed
using a Synapt G2-S mass spectrometer (Waters Corporation,
Manchester, UK) operated in data-independent acquisitionmode as
described in Ref. [51]. The spectral acquisition time in each mode
was 0.6 s with a 0.05-s interscan delay. In low energy MS mode,
data were collected at constant collision energy of 4 eV. In elevated
energy MSmode, the collision energy was ramped from 16 to 40 eV
during each 0.6-s integration. One cycle of low and elevated energy
data was acquired every 1.3 s. The radiofrequency (RF) amplitude
applied to the quadrupole mass analyzer was adjusted such that
ions from m/z 350 to 2000 were efﬁciently transmitted, ensuring
that any ions observed in the LC-MS data less than m/z 350 were
known to arise from dissociations in the collision cell. All samples
were analyzed in triplicate. Obtained raw datawere processed with
ProteinLynxGlobalServer v.3.0.1 and obtained spectra were
searching against the human UniProtKB/Swiss prot reference pro-
teome database (UniProtKBrelease 2012_07, 20,231 entries).
Sequence information of enolase 1 (S. cerevisiae) was added to the
data bases to conduct absolute quantiﬁcation (5) using the ISO
Quant software [50]. The experimental data were typically
searched with a 2-ppm precursor and 6-ppm production tolerance,
respectively, with one missed cleavage allowed and ﬁxed carba-
midomethylcysteine and variable methionine oxidation set as the
modiﬁcations.
2.8. Cell viability and nanoparticle uptake
Human micro vascular endothelial cells (HMEC-1; Centers for
Disease Control and Prevention) were cultured in Gibco™ MCDB
131 medium supplemented with 10% (v/v) FBS, 1% (v/v) Gluta-
MAX™ I (100; Life Technologies GmbH), 1 mg/mL hydrocholesterol
(Sigma Aldrich Chemie GmbH), 10 ng/mL epidermal growth factor
(Life Technologies GmbH). To determine the effects on cell meta-
bolism an ATPLite (PerkinElmer) assay was used. Cells were plated
onto a plastic matrix at a density of 1.2 104 cells/cm2 then allowed
to grow for 24 h prior to nanoparticle exposure. Nanoparticle
concentrations ranging from 5 to 50 mg/mL Fe(II)/(III) were pre-
incubated in water or in human plasma for 1 h at 4 C as
described above. All pelleted nanoparticles through the sucrose
were suspended in complete culture medium and transferred to
the cells and incubated for 24 h at 37 C in a 5% CO2 humidiﬁed
environment. After several washing steps, the cellular ATP level
was assessed according to the manufacturer's instructions. The
luminescent signals emerging from the transformation of D-lucif-
erin to oxyluciferin were measured using the LUMIstar Galaxy
(BMG LABATECH GmbH) system. The determined ATP levels after
nanoparticle exposure were normalized to non-treated control
cells. The internalization of nanoparticles was determined after
washing the cells during the ATP assay by microscopy (EVOS,
PEQLAB GMBH).
2.9. In vivo biodistribution in mice
During all experiments, animals were anesthetized with 2.5%
isoﬂurane (Aktavis). All experiments were in accordance with in-
ternational guidelines on the ethical use of animals and were
approved by the regional animal care committee (reg. number 02-
069/11). At day one 5.4e6.4 mg Fe(II/III) per gram bodyweight of the
different nanoparticle formulations were injected into female
athymic nude mice (Hsd:Athymic Nude-Foxn1nu) (Harlan Labora-
tories) intravenously. After 24 h, MRI measurements were per-
formed on a clinical 3T whole-body system (TIM Trio, Siemens
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[52] (Rapid Biomedical). During the MRI scan the animals were
monitored [53]. The used imaging sequence was a T*2-sensitive
spoiled gradient echo sequence with TE/TR/a ¼ 4.91 ms/16 ms/22,
a resolution of 0.31  0.31  0.25 mm3 and, with 2 averages, a total
acquisition time of 8 min 46 s. To measure the iron content of the
organs all mice were sacriﬁced for organ preparation after addi-
tional 24 h of incubation.
2.10. Measurements of organs iron content
Iron content of organs was determined using ﬂame atomic ab-
sorption spectrometry. The organs of threemice of each groupwere
isolated, each organwas cut into three slices, dried for 48 h at 37 C
and transferred to quartz glass tubes. During this transfer process,
the weight of the samples was determined. Incineration of the
dried organ slices was performed in a solution consisting of 3
fractions of 65% nitric acid (HNO3) and 2 fractions of 70% perchloric
acid (HClO4) at 250 C. The samples were dissolved in HNO3, after
mixing they were diluted in n/10 hydrogen chloride (HCl) (Roth)
directly in the analysis vials (Analytik Jena). Afterward, analysis of
the iron content was done using an AAS5 FL spectrometer (Analytik
Jena). All measurements were performed in triplicates. Standard
solutions (5e50 mmol Fe l 1 in 0.1 N hydrochloric acid; Merck)
were for calibration. The determined iron concentrations were used
for the mathematical correction of the amount of iron per gram of
the corresponding dried organ.
2.11. Statistical analysis
The data were analyzed using a paired Student's t-test. Statis-
tical signiﬁcance was calculated by comparing the different
experimental samples. P values < 0.05 are considered as signiﬁcant.
3. Results
3.1. The protein corona stabilizes Janus particles in suspension
Electron microscopy of the nanoparticle formulations (Fig. 1A)
revealed core sizes for the gold domain of 6.1 ± 0.3 nm and for the
iron oxide core of 16.1 ± 1.4 nm. The centrifugation process through
a sucrose cushion to isolate the protein-nanoparticle complexes
enhanced the aggregation of the nanoparticles in water. Interest-
ingly, the presence of a protein corona after nanoparticle incuba-
tion in human plasma stabilized all nanoparticle formulations,
preventing aggregation. This stabilization was indicated by a
reduced hydrodynamic diameter (Fig. 1B). Notably the NH2-func-
tionalization of the spherical Fe3O4-SiO2-PEG-NH2 nanoparticles
resulted in an assembly of pristine (i.e. not containing a protein
corona) nanoparticles into large agglomerates, which was not
observed after incubationwith plasma, indicating that the presence
of protein corona prevents nanoparticle agglomeration. All nano-
particle variants displayed a positively charged surface in water,
which was further enhanced by NH2-functionalization, for Au-thi-
ol@Fe3O4-SiO2-PEG from 5.3 to 17.9 mV and for the Fe3O4-SiO2-
PEGfrom 3.6e22.9 mV, likely due to a higher protonation level
caused by the NH2 groups (Fig. 1C). The NH2-functionalization of
the spherical variants increased the charge to a higher extent than
that of the JPs (Fig. 1C). Importantly, the zeta potentials became
negative after incubation in human plasma for all investigated
nanoparticles indicating the attachment of oppositely charged
plasma proteins (Fig. 1C). The amphiphilic Janus character reduced
the agglomeration tendency caused by NH2 groups, but generally
the particle morphology had no impact on stability and charge.3.2. NH2-functionalization modiﬁes the protein corona composition
The characterization of proteins constituting the protein corona
of Au-thiol@Fe3O4-SiO2-PEG nanoparticles provides essential data
concerning nanoparticle protein interactions due to the asym-
metric Janus structure. Analysis of corona components by SDS-
PAGE revealed relatively low protein binding for all nanoparticles,
which might be caused by the PEG surface functionalization
(Fig. 2A). In order to characterize the effect of incubation time on
the protein corona assembled on the surface of the particles, we
analyzed the corona composition after one (10) and sixty minutes
(600) of incubationwith plasma. Corona formation occurred rapidly
already within a minute for all nanoparticle formulations, indi-
cating the presence of major protein components with molecular
masses of 180, 100, 70, 45, and 20 kDa (Fig. 2A). The intense band
around 70 kDa represents serum albumin. There was no signiﬁcant
difference in protein adsorption between Au-thiol@Fe3O4-SiO2-PEG
and spherical Fe3O4-SiO2-PEG nanoparticles. Notably, we observed
additional bands above 100 and 180 kDa for NH2-functionalized
nanoparticles after sixty minutes of incubation (Fe3O4-SiO2-PEG-
NH2 and Au-thiol@Fe3O4-SiO2-PEG-NH2) (Fig. 2A). Since these
additional bands were not detectable for non-amine functionalized
JPs, we conclude that the association is NH2-functionalization
dependent (Fig. 2A). The kinetics of plasma protein/nanoparticle
binding showed an increase in protein adsorption with time for JPs
as compared to spherical nanoparticles irrespective of the presence
of NH2 groups (Fig. 2C). In summary, Au-thiol@Fe3O4-SiO2-PEG JPs
displayed a higher tendency to form a protein corona than spherical
Fe3O4-SiO2-PEG nanoparticles.
3.3. Janus character reduces adverse effects of NH2-
functionalization
To identify biologically relevant plasma proteins adsorbed to the
different nanoparticle formulations, we characterized the protein
corona using label-free quantitative liquid chromatography mass
spectrometry (LC-MS) [30]. Generally, serum albumin was identi-
ﬁed as the most abundant corona protein (Table 1). Surprisingly,
the NH2 groups at the Fe3O4 domain of the JP had a smaller impact
than the NH2 groups on spherical Fe3O4 particles (Au-thiol@Fe3O4-
SiO2-PEG vs. Fe3O4-SiO2-PEG-NH2) (Table 1). Histidine-rich glyco-
protein was detected as the most abundant protein on NH2-func-
tionalized Fe3O4 particles (Table 1). Classifying the corona proteins
according to their molecular mass and isoelectric point revealed
that proteins with sizes between 30 and 100 kDa constitute the
majority of all corona proteins (Table 1). Themost abundant protein
on Au-thiol@Fe3O4-SiO2-PEG, Au-thiol@Fe3O4-SiO2-PEG-NH2, and
Fe3O4-SiO2-PEG particles was serum albumin with a negative net
charge (IEP 5.86) indicating that nanoparticles with a zeta potential
between þ3 and þ20 mV preferentially attract negatively charged
proteins. In contrast, spherical Fe3O4-SiO2-PEG-NH2 particles dis-
played a zeta potential higher than þ20 mV which could explain
the binding of the neutral histidine-rich glycoprotein (Table 1).
Next, we performed a bioinformatic classiﬁcation of the corona
proteins categorized in groups according to their biological activ-
ities in the blood system (Fig. 3). Acute phase proteins like ceru-
loplasmin, haptoglobin, and serum amyloid are known as proteins
in inﬂammatory response [54,55]. Furthermore, proteins of the
complement system and coagulation proteins play an important
role in the human immune response [56,57]. Overall, Fe3O4-NH2
particles adsorbed less lipoproteins (compared to all other NPs),
acute phase proteins, and less proteins classiﬁed as “other”
(including serum albumin) (Fig. 3). In contrast, they adsorbed a
major portion of the coagulation protein “histidine-rich glycopro-
tein” and more proteins of the complement system compared to
Fig. 1. Schematic and microscopical depiction and the physicochemical characterization of the asymmetric Au@Fe3O4 and the spherical control nanoparticles. (A) Schematic
illustration of the used nanoparticle formulations with a thiole functionalized 3.5 nm sized gold core and silica-PEG coated 16 nm sized iron oxide core with additional NH2 groups
as functionalization. (B) TEM images of the nanoparticle formulations. Scale bar: 50 nm (C) Hydrodynamic diameters and (D) zeta potentials of the nanoparticle variants determined
after incubation in water or human plasma. PC: protein corona. *p < 0.05, **p < 0.005.
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alized and non NH2-functionalized) showed, independent of the
amine-groups, similar tendencies with a higher amount of proteins
from the complement system. Additionally, the corona constitution
did not display major changes compared to the Fe3O4-SiO2-PEG-
NH2-nanoparticles.3.4. The protein corona speciﬁcally enhances the biocompatibility of
JPs
Using human endothelial cells as a model system reﬂecting the
blood situation, we demonstrated the pathobiological relevance of
the corona. Cells incubated with corona-coated Au-thiol@Fe3O4-
SiO2-PEG nanoparticles showed increased cellular ATP levels
compared to cells treated with pristine particles (Fig. 4A, upper left
panel). This effect was independent of the presence of amino
groups (Fig. 4A, right panel). In contrast, spherical Fe3O4-SiO2-PEG
nanoparticles associated to a corona reduced the metabolic cell
activity (Fig. 4A, lower left panel). Interestingly, spherical nano-
particles exhibited a better biocompatibility without the protein
corona. Next, we monitored the effect of corona assembly on the
cellular nanoparticle uptake by optical microscopy. Our analysis
revealed an enhanced uptake of nanoparticles with coronas by
HMEC-1 cells, which was detectable for all nanoparticle variants
irrespective of the NH2-functionalization (Fig. 4B, right panels).3.5. Janus particles enable generation of T*2-contrast in vivo
To analyze distribution of JPs in vivo, they were injected intra-
venously via the tail vein (Fig. 5). Magnetic resonance imaging
demonstrated that Au-thiol@Fe3O4-SiO2-PEG JPs can be used for
in vivo imaging due to the generation of T*2-contrast similar to that
of the spherical Fe3O4-SiO2-PEG particles (Fig. 6A). Importantly,
mice that had been i.v. injected with JPs showed no cytotoxic or
thrombotic symptoms. Since PEGylation helped to prolong the
blood circulation time of nanoparticles [58] we also used PEG at the
Fe3O4 domains (Fe3O4-SiO2-PEG and Au-thiol@Fe3O4-SiO2-PEG).
MRI showed an accumulation of the Janus and spherical nano-
particles in the liver and spleen 24 h post injection (Fig. 6A), the
typical organs of the lymphatic and phagocytic active system. The
T*2-sensitive images demonstrated a strong intensity difference of
these organs between treated and native mice (Fig. 6A).
Determination of organ iron content ﬂame atomic absorption
spectroscopy indicated that only half of the applied JPs were taken
up by cells of the monocyte phagocyte system and transported into
the liver or were directly internalized by liver cells 48 h post in-
jection (Fig. 6B). Iron content of the liver was increased from
0.89 mg Fe/g tissue for native mice up to 1.18 mg Fe/g tissue for the
JP-treated and up to 1.11 mg Fe/g tissue for spherical nanoparticle-
treated mice (Fig. 6B). Notably, only approximately 58% of the
injected 136 mg Fe was transferred to the liver indicating that the
remaining particles probably still strayed through the body or were
taken up by other cells.
Fig. 2. NH2-functionalization modiﬁes corona composition. (A) SDS-PAGE stained with silver nitrate visualizes the bound proteins to the different nanoparticle formulations.
Molecular weight and incubation time is indicated. (B) SDS-PAGE visualizes whole plasma proteins. (C) Amount of bound proteins was determined using standard Bradford
technique. *p < 0.05.
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In the nanomedical ﬁeld, Janus particles provide a high potential
for the development strategies for tumor detection and therapy
[19,59,60]. However, it is unclear whether their special amphiphilic
properties and their asymmetric morphology impact their stability
in physiological environments. Upon contact with biological ﬂuids,
nanoparticles bind proteins, establishing a protein corona in as
little as 30 s [30]. Recently, several studies investigated the for-
mation of the protein corona on different types of nanoparticles
[30,61,62], including silica and polymer nanoparticles [30,38,63] as
well as gold and silver nanoparticles [62]. In addition to the
nanoparticle material, protein adsorption depends on nanoparticle
size and charge [41,63]. As the protein corona constitutes the “bio/
nano interface”, which affects the biological identity of the nano-
particles by determining their biocompatibility and transport
[29,30] we have characterized the formation of a protein corona on
Au-thiol@Fe3O4-SiO2-PEG JPs in detail using a quantitative prote-
omics approach and linked our corona data to effects on cells
in vitro and in vivo.
For our experiments, we selected Au-thiol@Fe3O4-SiO2-PEG JPs
with and without amino functionalization, as NH2 groups are
frequently used to link cargo ligands like drugs, proteins, DNA and
antibodies to nanoparticle surfaces [64e66] and compared them to
the respective spherical Fe3O4-SiO2-PEG control particles.
Stability measurements of the hydrodynamic diameter and the
zeta potentials revealed similar results for both JPs and spherical
control particles. Size and charge of JPs did not reveal major de-
viations from those of the spherical formulations, i.e. the amphi-
philic structure did not markedly affect the general
physicochemical characteristics of JPs. Interestingly, while NH2-
functionalized spherical Fe3O4-SiO2-PEG-NH2 nanoparticlesdispersed poorly in water, the Janus structure prevented agglom-
eration of Au-thiol@Fe3O4-SiO2-PEG-NH2 particles, thereby stabi-
lizing the particle in solution. A tendency to agglomeration caused
by surface NH2-groups has been described previously [15,67],
showing an increase of hydrodynamic diameters of amine-
modiﬁed polystyrene nanoparticles as compared to control nano-
particles [67]. As only the Fe3O4-SiO2-PEG-NH2 particles showed a
zeta potential >þ20 mV in water, we hypothesize that particle
aggregation is favored by charge effects. In the NH2-PEG function-
alized spherical Fe3O4 nanoparticles the terminal NH2 group
(pK z 9) will be protonated in buffered solution, i.e. the zeta po-
tential becomesmore positive, and therefore a large hydration shell
will develop around these spherical articles which leads to the
observed increase of the hydrodynamic radius. In contrast, in the
Au@Fe3O4 JPs only the iron oxide domain, functionalized with NH2-
terminated PEG is strongly involved in the interaction with the
solution, whereas the unfunctionalized Au domain is hydrophobic
and remains inert. This steric “protection” by the Au domain blocks
polar interaction with the solution and prevents a signiﬁcant in-
crease of the hydrodynamic radius. The smaller amount of surface
ligands (compared to the spherical particles) also prevents pro-
tonation of the terminal NH2 groups and a corresponding change of
the zeta potential.
Upon contact with serum proteins, all particles displayed a
negative surface charge. This may prevent inter-nanoparticle in-
teractions and thus aggregation via inter-particle van der Waal's
forces [68,69], thereby reducing nanoparticle agglomeration.
An in-depth characterization of adsorbed corona proteins is
essential to investigate corona effects on the biological identity of
JPs and their interactions with human cells. Towards this purpose,
we provide an overview of bound plasma proteins by 1D-SDS-
PAGE. Next, using an established label-free quantitative proteomics
Table 1










1 Serum albumin 71 5.86 Serum albumin 71 5.86 Serum albumin 71 5.86 Histidine-rich
glycoprotein
61 7.1
2 Fibrinogen alphachain 96 5.61 Fibrinogen alphachain 96 5.61 Ig gamma-1 chain C
region
37 8.18 Serum albumin 71 5.86
3 Fibrinogen betachain 57 8.25 Ig gamma-1 chain C
region
37 8.18 Fibrinogen alphachain 96 5.61 Plasminogen 93 6.91
4 Ig gamma-1 chain C region 37 8.18 Fibrinogen betachain 57 8.25 Fibrinogen betachain 57 8.25 Ig gamma-1 chain C
region
37 8.18
5 Fibrinogen gammachain 52 5.24 Fibrinogen gammachain 52 5.24 Fibrinogen
gammachain
52 5.24 Complement factor H 143 6.18
6 Apolipoprotein(a) 515 5.5 Igmuchain C region 49 6.33 Histidine-rich
glycoprotein
61 7.1 Igmuchain C region 49 6.33
7 Apolipoprotein A-I 31 5.43 Apolipoprotein(a) 515 5.5 Apolipoprotein A-I 31 5.43 Fibrinogen alphachain 96 5.61
8 Apolipoprotein B-100 516 6.58 Apolipoprotein A-I 31 5.43 Serotransferrin 79 6.75 Fibrinogen betachain 57 8.25
9 Serotransferrin 79 6.75 Ig kappa chain C region 11 5.5 Ig gamma-2 chain C
region
37 7.44 Fibrinogen gammachain 52 5.24
10 Complement C3 188 5.96 Apolipoprotein B-100 516 6.58 Apolipoprotein(a) 515 5.5 Ig kappa chain C region 11 5.5
11 Ig kappa chain C region 11 5.5 Complement C3 188 5.96 Complement C3 188 5.96 Apolipoprotein A-I 31 5.43





102 4.9 Serotransferrin 79 6.75 Alpha-2-
macroglobulin
164 6 Complement C3 188 5.96
14 Alpha-2-macroglobulin 164 6 Band 3
aniontransportprotein
102 4.9 Ig kappa chain C
region
11 5.5 Apolipoprotein(a) 515 5.5
15 Igmuchain C region 49 6.33 Histidine-rich
glycoprotein
61 7.1 Apolipoprotein B-100 516 6.58 Apolipoprotein B-100 516 6.58
16 Actin, cytoplasmic 1 42 5.14 Actin, cytoplasmic 1 42 5.14 Igmuchain C region 49 6.33 Serotransferrin 79 6.75
17 Ig alpha-1 chain C region 38 6.06 Ig gamma-2 chain C
region
37 7.44 Ig alpha-1 chain C
region
38 6.06 Ig gamma-2 chain C
region
37 7.44
18 Filamin-A 283 5.64 Ig gamma-3 chain C
region
42 7.79 Complement factor H 143 6.18 Ig alpha-1 chain C region 38 6.06
19 Spectrinalphachain,
erythrocytic 1
281 4.77 Haptoglobin 45 6.12 Actin, cytoplasmic 1 42 5.14 Filamin-A 283 5.64














Fig. 3. The Janus structure prevents the binding of coagulation proteins to NH2-functionalized iron oxide. Corona proteins identiﬁed by LC-MS and bioinformatically classiﬁed
according to their biological activities in the blood system. Incubation time in human plasma as indicated (1 min vs. 60 min). For abbreviations see Supplementary Table 1.
L. Landgraf et al. / Biomaterials 68 (2015) 77e8884workﬂow, we characterized the bound plasma components in
detail, identifying and quantifying 176 proteins in the corona of the
different nanoparticle formulations. We have previously shown
that the protein corona evolves quickly and stays rather constant at
prolonged exposure times [30]. Therefore, to investigate potential
time-dependent changes in the protein corona, we performedmass
spectrometric analysis of the protein corona at 1 min (as a model
for early exposure times) and 1 h, as a model for prolonged expo-
sure times. While we mostly did not observe major effects of the
incubation time, signiﬁcantly longer exposure times, or changes in
the incubation temperature might modify the corona composition
and therefore potentially affect particle stability in vivo.
Strikingly, NH2 surface functionalized spherical particles (Fe3O4-
SiO2-PEG-NH2) displayed a strongly enhanced binding of the
coagulation protein “histidine-rich glycoprotein” (HRG) and of
complement factor H. This may lead to a stronger activation of the
immune system in vivo. HRG is a plasma glycoprotein and regulates
numerous biological functions and interacts with cell surface re-
ceptors and organizes immune clearance and coagulation [57].
High levels of HRG are associated with thrombotic disorders [70]
suggesting pro-thrombotic effects of the Fe3O4-SiO2-PEG-NH2
nanoparticles. As the complement system participates in the
elimination of pathogens [56], increased binding of complement
factor Hmay increase clearance of the amine-functionalized Fe3O4-
SiO2-PEG-NH2. This steric “protection” by the hydrophobic Audomain of the JPs blocks any polar interactionwith the solution and
prevents an increase of the hydrodynamic radius. The smaller
amount of surface ligands (compared to the spherical particles) also
prevents protonation of the terminal NH2 groups and a corre-
sponding change of the zeta potential.
Our data indicate that while spherical nanoparticles may be
applied favorably for imaging, they may be less suited for drug
loading due to a potential induction of an immune response. In
contrast, NH2 groups at the Fe3O4 domain of the JPs did not lead to a
signiﬁcant difference in the distribution of the most abundant
corona proteins, rendering Au-thiol@Fe3O4-SiO2-PEG-NH2 JPs more
advantageous compared to spherical nanoparticles for drug de-
livery as well as imaging and therapy related applications.
To correlate the corona data with the possible effects in vitro, we
analyzed cellular ATP level as a marker of cell metabolism. Our
results indicated an improved biocompatibility of both JPs (Au-
thiol@Fe3O4-SiO2-PEG and Au-thiol@Fe3O4-SiO2-PEG-NH2) with a
protein corona after incubation in human plasma. They were better
tolerated than spherical nanoparticles with a corona and better
than pristine JPs, indicating a better biocompatibility of corona-
coated JPs. Furthermore, the generated corona leads to enhanced
uptake for all nanoparticle formulations. The formation of reactive
oxygen species caused by different nanoparticles resulted in
apoptotic processes was established [71,72]. A high level of reactive
oxygen species was also shown for spherical Fe3O4-SiO2-PEG in
Fig. 4. The protein corona enhances biocompatibility and uptake of Janus particles. (A) Relative cellular ATP levels were detected by ATPLite assay after 24 h. HMEC-1 treated with
the different nanoparticles with or without a protein corona (PC). Data were normalized to control values (no particle exposure), which were set as 100% ATP level. *p < 0.05 (B)
Uptake of nanoparticles into cells after incubation with 5 mg/mL Fe (II)/(III) for 24 h. Scale bars indicate 50 mm.
L. Landgraf et al. / Biomaterials 68 (2015) 77e88 85previous studies [15]. Interestingly, it was shown in literature that
the gold domain of Au-thiol@Fe3O4-SiO2-PEG JPs exhibited an anti-
oxidative potential against generated reactive oxygen species,
thereby improving the biocompatibility of the JPs [15]. This may be
especially important due to the higher cellular uptake of corona
coated JPs compared to pristine JPs and control particles, which is in
agreement with previous results showing an increased nano-
particle attachment and uptake into endothelial cells after corona
formation [30].
The in vivo biodistribution of nanoparticles critically impactspotential biomedical applications. However, only limited data
regarding the in vivo application of gold at magnetite hybrid par-
ticles are available, especially regarding their cellular uptake and
in vivo imaging abilities. Yang et al. previously developed Au@Fe3O4
hetero-nanostructures as afﬁbody based trimodality nanoprobes
(positron emission tomography, PET; optical imaging; and mag-
netic resonance imaging, MRI) for imaging of epidermal growth
factor receptor (EGFR) positive tumors and have shown that they
provided high speciﬁcity, sensitivity, and excellent tumor contrast
for both PET and MRI imaging [73]. In our study, we comparatively
Fig. 5. Schematic representation of the in vivo experimental setup. The time points
demonstrate injection of the respective probes, in vivo imaging and organ preparation.
y: animals were sacriﬁced. N ¼ 9.
L. Landgraf et al. / Biomaterials 68 (2015) 77e8886investigated the biodistribution of Au-thiol@Fe3O4-SiO2-PEG JPs
and spherical Fe3O4-SiO2-PEG control nanoparticles by MRI 24 h
post injection and by atomic adsorption spectroscopy in mice 48 h
post injection. Importantly, our data clearly demonstrated that the
JPs described in this produce T*2-contrast in vivo.
Previous studies investigating in vivo distribution and clearance
of nanoparticles demonstrated the accumulation of 12 nm sized
DMSA-coated magnetite nanoparticles after 3 h in the liver and
spleen [74]. Other studies showed that 55% of radiolabeled USPIOS
were found to accumulate in the liver already after 5 min and
decreased to almost zero after 48 h, revealing an elongated blood
life time supposedly caused by the PEGylation [75,76]. This is in
agreement with our observations that 58% of the applied JPs wereFig. 6. Au@Fe3O4 Janus particles generate similar T*2-contrast as compared to spherical Fe3O
representative mice for the different nanoparticle treatment groups 24 h post injection. Di
(blue), heart (red), (ii) liver (purple) and spleen (green). The white stripe in (i) indicate th
reduced MRI signal in the liver and spleen is clearly visible (tissue is black) in comparison to
MRI signal. (B) Atomic absorption spectrometry data of the isolated organs 48 h after nanopa
ﬁgure legend, the reader is referred to the web version of this article.)transported into the liver as determined by magnetic resonance
imaging 24 h and iron content measurements 48 h post injection.
Notably, despite PEGylation and the binding of serum albumin as a
dysopsonin, which is known to prevent the detection of nano-
particles by phagocytic active cells [77], Au-thiol@Fe3O4-SiO2-PEG
JPs were ﬁnally cleared by the body after 24 h.
In summary, the formation of a plasma protein corona on JPs
modiﬁed both size and surface charge. These changes affected both
internalization into endothelial cells and cytotoxicity. Furthermore,
the protein corona inﬂuenced the overall distribution throughout
the body. Compared to spherical particles, JPs displayed an
enhanced biocompatibility after uptake into cells. Importantly, the
amphiphilic Janus structure could prevent the adhesion of opsonins
to the NH2-groups indicating a prospective applicability for
selected biomedical applications.5. Conclusion
To understand nano-biointeractions that occur after intravenous
nanoparticle application, we investigated the behavior of Au-thio-
l@Fe3O4-SiO2-PEG Janus particles in a physiologically relevant
environment. We demonstrated that protein coronas were gener-
ated rapidly. Protein corona composition was strongly affected by
surface NH2-functionalization, while the Janus structure per se
signiﬁcantly reduced surface binding of coagulation proteins.
JPs exhibit enhanced biocompatibility after internalization,
whereas uptake was enhanced by the corona for all nanoparticle
formulations. We demonstrated the general capability of JPs to
generate T*2-contrast in the in vivo situation. Protein coronas
depending on nanoparticle shape, size and charge have important
implications for nanomedicine. Long-circulating nanoparticles are4 but offer the ability for multimodal imaging. (A) Magnetic resonance images of three
fferent tissues are marked as colored regions of interest: (i) The lung (yellow), muscle
e sectional plane shown in (ii). In both, coronal and transversal slices the drastically
the native images. At the same time other tissues (lung, muscle) show no changes in the
rticle application. N ¼ 9, *p < 0.05. (For interpretation of the references to colour in this
L. Landgraf et al. / Biomaterials 68 (2015) 77e88 87necessarily macrophage-evading, requiring efﬁcient strategies to
design stealthy particles by preventing opsonization. The rich op-
tions for designing JPs provide ample opportunities to optimize
particle characteristics for biomedical applications, e.g. by reducing
side effects of amine-functionalization and enhancing potential
anti-oxidative effects.
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